


## ML303

<b>Cat. No.:</b>	HY-126136		
<b>CAS No.:</b>	1638211-04-7		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>16</sub> F <sub>3</sub> N <sub>3</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	399.37		
<b>Target:</b>	Influenza Virus		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (312.99 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	2.5039 mL	12.5197 mL	25.0394 mL
<b>5 mM</b>	0.5008 mL	2.5039 mL	5.0079 mL
<b>10 mM</b>	0.2504 mL	1.2520 mL	2.5039 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

ML303 is a pyrazolopyridine influenza virus nonstructural protein 1 (NS1) antagonist (IC<sub>90</sub> = 155 nM), with an EC<sub>50</sub> of 0.7 μM for Influenza A virus H1N1<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

EC<sub>50</sub>: 0.7 μM (H1N1)<sup>[1]</sup>.

#### In Vitro

ML303 (20 μM, 6 h) treatment restore IFN-β mRNA levels in MDCK cells<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.  
Western Blot Analysis<sup>[1]</sup>

Cell Line:	MDCK cells infected with A/PR/8/34, at a MOI of 2, for 6 hours.
Concentration:	20 μM.
Incubation Time:	6 hours.

---

Result:	Restored IFN- $\beta$ mRNA levels in MDCK cells.
---------	--

---

## REFERENCES

---

[1]. Patnaik S, et al. Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists. *Bioorg Med Chem Lett*. 2019 May 1;29(9):1113-1119.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA